Scholarlink

<p>Lymph node (LN) metastasis remains a critical determinant of cancer progression and prognosis, yet surgical interventions result in adverse effects. In this preclinical study, we investigated a minimally invasive therapeutic approach combining magnetic hyperthermia (MH) with a lymphatic drug delivery system (LDDS) using iron oxide nanoparticles (Resovist<sup>®</sup>). A custom-built MH device precisely regulated LN temperature at 45&#xa0;°C. Using a mouse model (MXH10/Mo/lpr) of tumor-suspicious LN (ts-LN) metastasis, Resovist<sup>®</sup> was intranodally administered, followed by MH treatment. This combination significantly suppressed tumor growth in ts-LN and reduced lung metastasis, with enhanced M1 macrophage polarization and antitumor immune responses. Histopathology confirmed tumor necrosis and localized nanoparticle deposition, while qPCR of spleen tissue indicated differential immune modulation. No overt systemic toxicity was observed. The results demonstrated that this theranostic approach allows for real-time thermal control and effective regional tumor inhibition. The technique holds promise for early-stage cancer patients, offering a non-invasive, image-guided alternative to surgical LN resection with the potential for clinical translation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Magnetic hyperthermia using iron oxide nanoparticles via LDDS suppressed lymph node and lung metastasis in a mouse model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Akihiro Kuwahata,
  • Ariunbuyan Sukhbaatar,
  • Akihiro Shikano,
  • Loi Tonthat,
  • Takayuki Kagami,
  • Riku Shinohara,
  • Shiro Mori,
  • Shin Yabukami,
  • Tetsuya Kodama

摘要

Lymph node (LN) metastasis remains a critical determinant of cancer progression and prognosis, yet surgical interventions result in adverse effects. In this preclinical study, we investigated a minimally invasive therapeutic approach combining magnetic hyperthermia (MH) with a lymphatic drug delivery system (LDDS) using iron oxide nanoparticles (Resovist®). A custom-built MH device precisely regulated LN temperature at 45 °C. Using a mouse model (MXH10/Mo/lpr) of tumor-suspicious LN (ts-LN) metastasis, Resovist® was intranodally administered, followed by MH treatment. This combination significantly suppressed tumor growth in ts-LN and reduced lung metastasis, with enhanced M1 macrophage polarization and antitumor immune responses. Histopathology confirmed tumor necrosis and localized nanoparticle deposition, while qPCR of spleen tissue indicated differential immune modulation. No overt systemic toxicity was observed. The results demonstrated that this theranostic approach allows for real-time thermal control and effective regional tumor inhibition. The technique holds promise for early-stage cancer patients, offering a non-invasive, image-guided alternative to surgical LN resection with the potential for clinical translation.